Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin in Advanced Salivary Gland Carcinomas
NCT00004163Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 1999
- Primary completion
- Sep 2001
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in salivary gland carcinoma (SGC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate at 2 years. Started Oct 1999; status: completed.
02
Drugs
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT00004163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004163.